Furthermore, AZD8797 was described as an allosteric inhibitor of CX3CR1 [37]; however, it is not known whether it leads to the same changes in the receptor conformation and affects the downstream signaling cascades in all tested ovarian cancer cell lines similarly. This evidence concerns the gene CX3CR1 and ovarian cancer.